There are currently 40 active clinical trials seeking participants for Brain Tumor research studies. The states with the highest number of trials for Brain Tumor participants are California, New York, Florida and Texas.
Multi-Parametric Quantitative MR Imaging in Evaluation of Brain Tumors
Recruiting
The purpose of the research study is to test new methods that could improve diagnosis and assessment of brain tumors. One of these methods is a new MR (magnetic resonance) imaging technique called magnetic resonance fingerprinting (MRF), which allows for rapidly scanning the patient and provides quantitative information on tumor tissue. The investigators will compare the data gathered from MR Fingerprinting with other imaging tests, clinical information, treatment details and biopsy results to e... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Brain Tumor
A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas
Recruiting
The purpose of this study is to evaluate whether treating glioblastoma patients with sitagliptin can improve immune response against the tumor by targeting specific immune cells called myeloid-derived suppressor cells (MDSCs) that suppress your body's natural immune response against cancer. Sitagliptin is an investigational drug for this condition that works by inhibiting an enzyme called dipeptidyl peptidase 4 (DPP-4), which MDSCs rely on to enter the brain and function. While sitagliptin is F... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2025
Locations: Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland, Ohio
Conditions: Glioblastoma, Brain Tumor
Development of MRF for Characterization of Brain Tumors After Radiotherapy
Recruiting
The purpose of this study is to discover the potential convenience and ease of using a Magnetic Resonance Imaging (MRI) technique, named Magnetic Resonance Fingerprinting (or MRF), to achieve high-quality images within a short scan time of 5 min for viewing the entire brain. This is an advanced quantitative assessment of brain tissues. This method is being applied with IVIM MRI to be able to tell the difference between a brain with radiation necrosis and a brain with tumor recurrence. Participan... Read More
Gender:
ALL
Ages:
Between 21 years and 60 years
Trial Updated:
06/05/2025
Locations: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio +1 locations
Conditions: Brain Tumor, Brain Necrosis, Brain Metastases, Glioma
Study of Letrozole in Recurrent Gliomas
Recruiting
The purpose of this study is to determine the ability of letrozole to penetrate the blood brain barrier and concentrate in gliomas.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2023
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Brain Tumor
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
Recruiting
This research study is studying troriluzole as a possible treatment for recurrent glioblastoma. The name of the study drug involved in this research study is: -Troriluzole (a tripeptide prodrug of riluzole)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +2 locations
Conditions: Glioblastoma, Recurrent Glioblastoma, Brain Tumor
Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy
Recruiting
This research study is studying Proton Radiation as a possible treatment for brain tumor. The radiation involved in this study is: -Proton Radiation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Brain Tumor
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
Recruiting
The goal of this Phase 3 clinical trial is to compare the efficacy of niraparib versus temozolomide (TMZ) in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma multiforme (GBM). The main questions it aims to answer are: Does niraparib improve progression-free survival (PFS) compared to TMZ? Does niraparib improve overall survival (OS) compared to TMZ? Participants will be randomly assigned to one of two treatment arms: niraparib or TMZ. * study drug (Niraparib) or * comp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Ivy Brain Tumor Center, Phoenix, Arizona +50 locations
Conditions: Glioblastoma, GBM, Brain Neoplasms, Adult, Malignant, Brain Tumor
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
Recruiting
This Phase 2 clinical trial will study RVP-001, a new manganese-based MRI contrast agent, in people who are known to have gadolinium-enhancing central nervous system (CNS) lesions, for example brain tumors or multiple sclerosis. The goal of this study is to assess safety, efficacy, and pharmacokinetics of RVP-001 at three dose levels. The study will also compare RVP-001 imaging to gadolinium-based contrast agent (GBCA) imaging. A single dose of RVP-001 will be administered to each subject. Subj... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/12/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut +4 locations
Conditions: Central Nervous System (CNS) Lesions, Brain Metastases, Brain Neoplasms, Brain Neoplasms, Benign, Brain Tumor, Primary, Brain Tumor, Recurrent, Brain Tumors, Brain Cancer, Brain Tumor, Brain Neoplasm, Primary, Multiple Sclerosis, Multiple Sclerosis Brain Lesion, Neurofibroma, Acoustic Neuroma, CNS Tumor, CNS Lesion, CNS Metastases, CNS Cancer, CNS Lymphoma, Von Hippel Lindau, Meningioma, Glioma, Schwannomas, Neuroinflammation, Neoplasia
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
Recruiting
Background: Diffuse gliomas are tumors that affect the brain and spinal cord. Gliomas that develop in people with certain gene mutations (IDH1 or IDH2) are especially aggressive. Better treatments are needed. Objective: To see if a study drug (zotiraciclib) is effective in people with recurrent diffuse gliomas who have IDH1 or IDH2 mutations. Eligibility: People aged 15 years and older with diffuse gliomas that returned after treatment. They must also have mutations in the IDH1 or IDH2 gene... Read More
Gender:
ALL
Ages:
15 years and above
Trial Updated:
08/05/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Brain Tumor, Cancer
Visual Plasticity Following Brain Lesions
Recruiting
The VIBRANT (Vision Improvement through Behavioral Rehabilitation And Neuroplasticity Training) study is a prospective, double-blind, crossover design (within-subject) in participants with homonymous hemianopia-a type of visual field loss resulting from damage to the post-chiasmatic visual pathways. It aims to investigate whether transcranial random noise stimulation (tRNS) combined with perceptual learning-based training has potential for improving visual impairments.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Georgetown University Medical Center, Washington, District of Columbia
Conditions: Visual Field Defect, Stroke, Hemianopia, Quadrantanopia, Cortical Blindness, Brain Tumor, Traumatic Brain Injury, Visual Field Defect, Peripheral
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Recruiting
This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumor types with a confirmed MTAP loss. The study drug, TNG456, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 191 participants.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +5 locations
Conditions: Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor, Non-Small Cell Adenocarcinoma, Lung Cancer, Brain Tumor
Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)
Recruiting
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type2.0/2.1 in combination with Doxorubicin therapy for the treatment of DIPG in pediatric patients
Gender:
ALL
Ages:
Between 5 years and 21 years
Trial Updated:
07/23/2025
Locations: Children's National Medical Center, Washington, District of Columbia +2 locations
Conditions: Brain Tumor